Octri-Lar Depot Injection
Marketer
Sayre Therapeutics Pvt Ltd
Salt Composition
Octreotide acetate (30mg)
Overview Octri-Lar Depot Injection
Somatostatin analog Octri-Lar Depot Injection treats acromegaly, carcinoid tumors, and bleeding esophageal varices, further preventing post-pancreatic surgery complications. Administration is exclusively by a healthcare provider; self-injection is strictly prohibited. Dosage and frequency are determined solely by your physician. Consistent use maximizes therapeutic effects; discontinue only under medical guidance. Common side effects include diarrhea, abdominal pain, nausea, constipation, gas, and headache. Report persistent or worsening side effects. Prior to treatment, disclose any liver conditions and all other medications currently in use to your doctor.
Primary Ingredients of Octri-Lar Depot Injection
No text provided. Please provide the text you would like me to rephrase.
Uses of Octri-Lar Depot Injection
Overgrowth of the extremities due to excess growth hormone | Neuroendocrine tumors producing excess hormones | Life-threatening esophageal vein rupture
Major Benefits of Octri-Lar Depot Injection:
This medication will be administered by your healthcare provider. Self-medication is strongly discouraged.
Common Side effects of Octri-Lar Depot Injection:
- Diarrhea
- Abdominal pain
- Nausea
- Constipation
- Flatulence
- Headache
- Increased glucose level in blood
- Injection site reaction
How to use Octri-Lar Depot Injection:
This medication will be administered by your healthcare provider. Self-medication is strongly discouraged.
How Octri-Lar Depot Injection works:
Octri-Lar Depot Injection mimics the action of somatostatin, a naturally occurring human hormone regulator that suppresses the activity of various hormones, including growth hormone. This injection additionally reduces esophageal bleeding via vasoconstriction.
SAFETY ADVICE
AlcoholCONSULT YOUR DOCTOR
Alcohol consumption alongside Octri-Lar Depot Injection may pose unknown risks. Seek medical advice before combining them.
PregnancySAFE IF PRESCRIBED
The use of Octri-Lar Depot Injection during pregnancy is typically deemed safe. Preclinical trials in animals revealed minimal or no harmful consequences to fetal development; nevertheless, clinical data from human trials are scarce.
Breast feedingSAFE IF PRESCRIBED
Administration of Octri-Lar Depot Injection while breastfeeding appears to pose minimal risk. Available human data indicate negligible infant exposure.
DrivingSAFE
Driving ability is typically unaffected by Octri-Lar Depot Injection.
KidneySAFE IF PRESCRIBED
Octri-Lar Depot Injection poses no safety concerns for patients with renal impairment; dosage modification is unnecessary.
LiverCAUTION
Patients with hepatic impairment should receive Octri-Lar Depot Injection with careful monitoring. Dosage modification may be necessary. Physician consultation is advised.
What if you forget to take Octri-Lar Depot Injection :
Should you forget a scheduled Octri-Lar Depot Injection, administer it at your earliest convenience. If, however, your next dose is imminent, omit the missed injection and resume your usual dosing regimen. Never take a double dose.
Facts to Know About Octri-Lar Depot Injection
| Label | Value |
|---|---|
| Chemical Category | Somatostatin analogs |
| Developing Habits | No. |
| Treatment Category | Endocrine Signals |
| Actions | Somatostatin analogs |
3,018 People bought this recently